Overview

Testosterone Replacement for Male Opioid Agonist Maintained Patients

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
0
Participant gender:
Male
Summary
This study is designed to develop an effective treatment intervention for chronic pain, symptomatic hypogonadism, and opioid addiction
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yale University
Treatments:
Analgesics, Opioid
Methyltestosterone
Testosterone
Testosterone 17 beta-cypionate
Testosterone enanthate
Testosterone undecanoate
Criteria
Inclusion Criteria:

- Between 18 and 50 years of age

- Male buprenorphine- or methadone-maintained patients at the APT Foundation

- Moderate to severe chronic pain

- Meet criteria for symptomatic hypogonadism

- Understand English

- Interested in receiving testosterone replacement

Exclusion Criteria:

- Current suicide or homicide risk

- Life-threatening or unstable medical condition

- Known or suspected prostate or chest cancer or history of polycythemia